AGMB

Piper Sandler initiated coverage of AgomAb Therapeutics NV with a rating of Overweight and set a new price target of $60.00

Cantor Fitzgerald initiated coverage of AgomAb Therapeutics NV with a rating of Overweight

6-K - Agomab Therapeutics NV (0002020932) (Filer)

Antwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026. "We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors," said David Epstein, Chairman of the Board of Agomab. "Marino brings extensive experience building, financing and leading inno

6-K - Agomab Therapeutics NV (0002020932) (Filer)

-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD), including Novel Primary Endpoint of Endoscopic Passability -- -- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b Idiopathic Pulmonary Fibrosis (IPF) Study Cohort with AGMB-447 Expected in Coming Months -- -- On Track to Initiate NOV-ERA Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in with AGMB-447 in IPF in Second Half of 2026 -- -- Cash and Cash Investments at June 30, 2026 of €252 Million, including $208 Million in Gross

B. Riley Securities initiated coverage of AgomAb Therapeutics NV with a rating of Buy and set a new price target of $34.00

6-K - Agomab Therapeutics NV (0002020932) (Filer)

-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expected to be dosed in the second half of 2026 -- Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing C

H.C. Wainwright initiated coverage of AgomAb Therapeutics NV with a rating of Buy and set a new price target of $35.00

6-K - Agomab Therapeutics NV (0002020932) (Filer)

Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM) held on Tuesday, May 26, 2026. All items on the agenda were approved, including: Approval of the statutory financial statements for the financial year ended December 31, 2025.Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025.Reappointment of Mr. Ohad Hammer as a member of the Board of Directors for a term of one year.Rea

SCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)

SCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)

Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences: ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects' on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Fir

SCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)

6-K - Agomab Therapeutics NV (0002020932) (Filer)

-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease (FSCD) ---- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 ---- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Hal

20-F - Agomab Therapeutics NV (0002020932) (Filer)

SCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)

Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company's investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This patent provides intellectual property (IP) protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions. "The issuance of th

3 - Agomab Therapeutics NV (0002020932) (Issuer)

3 - Agomab Therapeutics NV (0002020932) (Issuer)

3 - Agomab Therapeutics NV (0002020932) (Issuer)

3 - Agomab Therapeutics NV (0002020932) (Issuer)